Expanding on the capabilities of our early adoption of our fleet of digital pathology scanners, Alverno is leading the way as the first laboratory in the Midwest, and one of the first ten labs in the country, to offer the Ibex Platform trusted suite of artificial intelligence (AI) solutions. Our implementation includes AI-powered solutions for cancer diagnosis across multiple tissue biopsy types, including prostate, breast, and gastric, and will support our pathologists in providing the utmost quality of care for our patients.
Powered by
Learn more about on how we can partner together to provide patients with quality care!
Now Live
Ibex Prostate
Improving the detection and grading of prostate cancer in prostate biopsies
AI-powered tools for:
- Cancer detection
- Gleason grading
- Perineural invasion identification
- Tumor measurement
The implementation of the platform yields a 32% reduction in major discrepancy rate.1,2,3
Clinical validation study demonstrated high accuracy4:
| Test | Performance |
|---|---|
| Cancer Detection | AUC = 0.991 |
| G7+ | AUC = 0.941 |
| G5 | AUC = 0.971 |
| PNI | AUC = 0.957 |
Coming Soon
Ibex Breast
Improving the detection and grading of breast cancer in breast biopsies
AI-powered tools for:
- Invasive cancer detection
- In-situ cancer detection
- Cancer subtype detection
- Identification of tumor-infiltrating lymphocytes, lymphovascular invasion, microcalcifications, etc.
Implementation of the platform yields a 29% reduction in major discrepancy rate.5
Clinical validation study demonstrated high accuracy6:
| Detection | AUC | Specificity | Sensitivity |
|---|---|---|---|
| Invasive Breast Cancer | 0.990 | 93.6% | 95.5% |
| DCIS | 0.980 | 93.8% | 93.2% |
| IDC vs ILC | 0.973 | 92.7% | 92.9% |
| IG/HG DCIS vs ADH/LG DCIS | 0.921 | 84.8% | 84.1% |
| Detection | AUC | Specificity | Sensitivity |
|---|---|---|---|
| Invasive Breast Cancer | 0.990 | 93.6% | 95.5% |
| DCIS | 0.980 | 93.8% | 93.2% |
| IDC vs ILC | 0.973 | 92.7% | 92.9% |
| IG/HG DCIS vs ADH/LG DCIS | 0.921 | 84.8% | 84.1% |
Coming Soon
Ibex Gastric
Improving the detection and grading of gastric cancer in stomach biopsies
AI-powered tools for:
- Cancer detection
- H. pylori and H. pylori related gastritis detection
The implementation of the platform yields a 25% reduction in major discrepancy rate.7
Clinical validation study demonstrated high accuracy8:
| Detection | AUC | Specificity | Sensitivity |
|---|---|---|---|
| HG Dysplasia / Carcinoma / HG Lymphoma7 | 0.986 | 88.7% | 96.3% |
| H. Pylori8 | 0.996 | 90.5% | 91.1% |
- Borkowski et al. Presented at the Florida Society of Pathologists 2023
- Comperat et al, Virchows Arch 2021, 479 (Suppl 1), S60-S61
- Raoux et al. Presented at USCAP 2021
- Pantanowitz et al. THE LANCET Digital Health Aug 2020
- Vincent-Salomon et al, Virchows Arch 2022, 481 (Suppl 1), S48
- Sandbank et al., npj Breast Cancer, December 2022
- Calvo et al. Presented at EDCP 2022
- Sandbank et al. Lab Invest. 2022. Mar;102 (Suppl 1):513-514